Get started
Author

Tove Henriksen

Observed names: Henriksen T, Henriksen, Tove, T Henriksen, T. Henriksen
Observed institutions: University of Copenhagen, Frederiksberg Hospital, Bispebjerg Hospital, Copenhagen University Hospital, University of Oxford, International Parkinson and Movement Disorder Society, Capital Region of Denmark
ORCID: 0000-0002-5171-1166
Observed ORCID: 0000-0002-5171-1166
OpenAlex ID: A5071169930
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
2018 · Regina Katzenschlager, Werner Poewe, et al. · The Lancet Neurology · 357
Euro I nf: A M ulticenter C omparative O bservational S tudy of A pomorphine and L evodopa I nfusion in P arkinson's D isease
2014 · Pablo Martinez‐Martin, Prashanth Reddy, et al. · Movement Disorders · 259
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry
2017 · Angelo Antonini, Werner Poewe, et al. · Parkinsonism & Related Disorders · 228
PDF
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program
2015 · P. Odin, K. Ray Chaudhuri, et al. · Parkinsonism & Related Disorders · 210
PDF
EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease
2019 · Haidar S. Dafsari, Pablo Martinez‐Martin, et al. · Movement Disorders · 191
PDF
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations
2015 · Claudia Trenkwalder, K. Ray Chaudhuri, et al. · Parkinsonism & Related Disorders · 176
Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect
2011 · Pablo Martinez-Martin, Prashanth Reddy, et al. · Journal of Parkinson s Disease · 141
PDF
A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short‐ and long‐acting dopamine agonists
2016 · A. Rizos, A. Sauerbier, et al. · European Journal of Neurology · 104
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
2021 · Regina Katzenschlager, Werner Poewe, et al. · Parkinsonism & Related Disorders · 88
PDF
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
2018 · Per Odin, K. Ray Chaudhuri, et al. · npj Parkinson s Disease · 83
PDF
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications
2021 · Angelo Antonini, Per Odin, et al. · Parkinsonism & Related Disorders · 67
PDF
Reduced contralateral hemispheric flow measured by SPECT in cerebellar lesions: crossed cerebral diaschisis
1993 · Sönmezoǧlu K, Sperling B, et al. · Acta Neurologica Scandinavica · 58
Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years
2024 · Stefanie T. Jost, Salima Aloui, et al. · JAMA Network Open · 50
PDF
Practical management of adverse events related to apomorphine therapy
2016 · Roongroj Bhidayasiri, Pedro J. Garcia Ruiz, et al. · Parkinsonism & Related Disorders · 49
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
2021 · Stefanie T. Jost, Veerle Visser-Vandewalle, et al. · npj Parkinson s Disease · 48
PDF
Impact of advanced Parkinson’s disease on caregivers: an international real-world study
2023 · Pablo Martinez-Martin, Matej Skorvanek, et al. · Journal of Neurology · 47
PDF
Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy
2016 · Roongroj Bhidayasiri, Kamolwan Boonpang, et al. · Parkinsonism & Related Disorders · 47
Infusion Therapies in the Treatment of Parkinson’s Disease
2023 · Teus van Laar, K. Ray Chaudhuri, et al. · Journal of Parkinson s Disease · 38
PDF
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review
2023 · Harmen R. Moes, Tove Henriksen, et al. · Journal of Neural Transmission · 37
PDF
Clinical Insights Into Use of Apomorphine in Parkinson’s Disease: Tools for Clinicians
2014 · Tove Henriksen · Neurodegenerative Disease Management · 34
Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
2023 · Tove Henriksen, Regina Katzenschlager, et al. · Journal of Neural Transmission · 30
PDF
A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease
2015 · Kallol Ray Chaudhuri, Antoniya Todorova, et al. · Movement Disorders Clinical Practice · 30
PDF
Access and Use of Device‐Aided Therapies for Parkinson’s Disease in Denmark
2020 · Tove Henriksen, Kim Peder Dalhoff, et al. · Movement Disorders Clinical Practice · 27
Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study
2021 · Louise M Jørgensen, Tove Henriksen, et al. · Journal of Cerebral Blood Flow & Metabolism · 26
Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation
2021 · Tove Henriksen, Harry Staines · Journal of Personalized Medicine · 25
PDF
Works count: 74
Citation count: 2,657
H-index: 25
I10-index: 35
Year
Topic
Type